Nem alkoholos zsírmáj és zsírmá jhepatitis

Translated title of the contribution: Non-alcoholic fatty liver disease and steatohepatitis

G. Pár, Gábor Horváth, A. Pár

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, the hepatic manifestations of metabolic syndrome with close association with inzulin resistance and obesity, are the most common liver diseases, affecting up to a third of the population worldwide. They confer increased risk for hepatocellular carcinoma as well as cardiovascular diseases. The review aims to summarize advances in epidemiology, pathogenesis and clinical management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Besides liver biopsy and biomarkers, a novel non-invasive diagnostic tool the called "controlled attenuation parameter" measuring the attenuation of ultrasound generated by the transient elastography transducer, can quantitatively assess the hepatic fat content and differentiate between steatosis grades. At the same time, liver stiffness (fibrosis) can also be evaluated. The authors present their own results obtained with the latter procedure. In non-alcoholic fatty liver disease, the lifestyle intervention, weight loss, diet and exercise supported by cognitive behavioural therapy represent the basis of management. Components of metabolic syndrome (obesity, dyslipidaemia, diabetes and arterial hypertension) have to be treated. Although there is no approved pharmacological therapy for NASH, it seems that long lasting administration of vitamin E in association with high dose ursodeoxycholic acid may be beneficial. In addition, omega-3 polyunsaturated fatty acid substitution can also decrease liver fat, however, the optimal dose is not known yet. Further controlled clinical studies are warranted to establish the real value of any suggested treatment modalities for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, although these are in experimental phase yet. Orv. Hetil., 2013, 154, 1124-1134.

Original languageHungarian
Pages (from-to)1124-1134
Number of pages11
JournalOrvosi Hetilap
Volume154
Issue number29
DOIs
Publication statusPublished - Jul 1 2013

Fingerprint

Fatty Liver
Liver
Obesity
Fats
Reducing Diet
Elasticity Imaging Techniques
Ursodeoxycholic Acid
Omega-3 Fatty Acids
Cognitive Therapy
Dyslipidemias
Transducers
Unsaturated Fatty Acids
Vitamin E
Liver Cirrhosis
Life Style
Liver Diseases
Hepatocellular Carcinoma
Epidemiology
Cardiovascular Diseases
Biomarkers

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nem alkoholos zsírmáj és zsírmá jhepatitis. / Pár, G.; Horváth, Gábor; Pár, A.

In: Orvosi Hetilap, Vol. 154, No. 29, 01.07.2013, p. 1124-1134.

Research output: Contribution to journalArticle

Pár, G. ; Horváth, Gábor ; Pár, A. / Nem alkoholos zsírmáj és zsírmá jhepatitis. In: Orvosi Hetilap. 2013 ; Vol. 154, No. 29. pp. 1124-1134.
@article{f5f8d1efe59c4a8287ad5379f2490e8c,
title = "Nem alkoholos zs{\'i}rm{\'a}j {\'e}s zs{\'i}rm{\'a} jhepatitis",
abstract = "Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, the hepatic manifestations of metabolic syndrome with close association with inzulin resistance and obesity, are the most common liver diseases, affecting up to a third of the population worldwide. They confer increased risk for hepatocellular carcinoma as well as cardiovascular diseases. The review aims to summarize advances in epidemiology, pathogenesis and clinical management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Besides liver biopsy and biomarkers, a novel non-invasive diagnostic tool the called {"}controlled attenuation parameter{"} measuring the attenuation of ultrasound generated by the transient elastography transducer, can quantitatively assess the hepatic fat content and differentiate between steatosis grades. At the same time, liver stiffness (fibrosis) can also be evaluated. The authors present their own results obtained with the latter procedure. In non-alcoholic fatty liver disease, the lifestyle intervention, weight loss, diet and exercise supported by cognitive behavioural therapy represent the basis of management. Components of metabolic syndrome (obesity, dyslipidaemia, diabetes and arterial hypertension) have to be treated. Although there is no approved pharmacological therapy for NASH, it seems that long lasting administration of vitamin E in association with high dose ursodeoxycholic acid may be beneficial. In addition, omega-3 polyunsaturated fatty acid substitution can also decrease liver fat, however, the optimal dose is not known yet. Further controlled clinical studies are warranted to establish the real value of any suggested treatment modalities for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, although these are in experimental phase yet. Orv. Hetil., 2013, 154, 1124-1134.",
keywords = "controlled attenuated parameter, controlled attenuated parameter (CAP), nem alkoholos zs{\'i}rm{\'a}j, non-alcoholic fatty liver, non-alcoholic steatohepatitis, zs{\'i}rm{\'a}jhepatitis",
author = "G. P{\'a}r and G{\'a}bor Horv{\'a}th and A. P{\'a}r",
year = "2013",
month = "7",
day = "1",
doi = "10.1556/OH.2013.29626",
language = "Hungarian",
volume = "154",
pages = "1124--1134",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "29",

}

TY - JOUR

T1 - Nem alkoholos zsírmáj és zsírmá jhepatitis

AU - Pár, G.

AU - Horváth, Gábor

AU - Pár, A.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, the hepatic manifestations of metabolic syndrome with close association with inzulin resistance and obesity, are the most common liver diseases, affecting up to a third of the population worldwide. They confer increased risk for hepatocellular carcinoma as well as cardiovascular diseases. The review aims to summarize advances in epidemiology, pathogenesis and clinical management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Besides liver biopsy and biomarkers, a novel non-invasive diagnostic tool the called "controlled attenuation parameter" measuring the attenuation of ultrasound generated by the transient elastography transducer, can quantitatively assess the hepatic fat content and differentiate between steatosis grades. At the same time, liver stiffness (fibrosis) can also be evaluated. The authors present their own results obtained with the latter procedure. In non-alcoholic fatty liver disease, the lifestyle intervention, weight loss, diet and exercise supported by cognitive behavioural therapy represent the basis of management. Components of metabolic syndrome (obesity, dyslipidaemia, diabetes and arterial hypertension) have to be treated. Although there is no approved pharmacological therapy for NASH, it seems that long lasting administration of vitamin E in association with high dose ursodeoxycholic acid may be beneficial. In addition, omega-3 polyunsaturated fatty acid substitution can also decrease liver fat, however, the optimal dose is not known yet. Further controlled clinical studies are warranted to establish the real value of any suggested treatment modalities for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, although these are in experimental phase yet. Orv. Hetil., 2013, 154, 1124-1134.

AB - Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, the hepatic manifestations of metabolic syndrome with close association with inzulin resistance and obesity, are the most common liver diseases, affecting up to a third of the population worldwide. They confer increased risk for hepatocellular carcinoma as well as cardiovascular diseases. The review aims to summarize advances in epidemiology, pathogenesis and clinical management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Besides liver biopsy and biomarkers, a novel non-invasive diagnostic tool the called "controlled attenuation parameter" measuring the attenuation of ultrasound generated by the transient elastography transducer, can quantitatively assess the hepatic fat content and differentiate between steatosis grades. At the same time, liver stiffness (fibrosis) can also be evaluated. The authors present their own results obtained with the latter procedure. In non-alcoholic fatty liver disease, the lifestyle intervention, weight loss, diet and exercise supported by cognitive behavioural therapy represent the basis of management. Components of metabolic syndrome (obesity, dyslipidaemia, diabetes and arterial hypertension) have to be treated. Although there is no approved pharmacological therapy for NASH, it seems that long lasting administration of vitamin E in association with high dose ursodeoxycholic acid may be beneficial. In addition, omega-3 polyunsaturated fatty acid substitution can also decrease liver fat, however, the optimal dose is not known yet. Further controlled clinical studies are warranted to establish the real value of any suggested treatment modalities for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, although these are in experimental phase yet. Orv. Hetil., 2013, 154, 1124-1134.

KW - controlled attenuated parameter

KW - controlled attenuated parameter (CAP)

KW - nem alkoholos zsírmáj

KW - non-alcoholic fatty liver

KW - non-alcoholic steatohepatitis

KW - zsírmájhepatitis

UR - http://www.scopus.com/inward/record.url?scp=84880396457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880396457&partnerID=8YFLogxK

U2 - 10.1556/OH.2013.29626

DO - 10.1556/OH.2013.29626

M3 - Article

VL - 154

SP - 1124

EP - 1134

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 29

ER -